ABSTRACT
Introduction
The incretin effect denotes the phenomenon whereby oral glucose stimulation elicits a higher insulin secretory response compared to "isoglycemic" intravenous glucose, and is explained by the actions of the intestinally-derived incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) (1) . In patients with type 2 diabetes, this incretin effect is impaired (2) , mainly because diabetic ß-cells no longer respond to GIP (3; 4) . However, the effects of GLP-1 in type 2 diabetes are impaired (5), but better retained in comparison to healthy control subjects (4) , and incretin-based medications successfully lower plasma glucose in type 2-diabetic patients (1) . Activation of GLP-1 receptors stimulates insulin secretory responses (4; 5) and suppresses glucagon (4; 6), with additional effects on gastro-intestinal motility (7; 8) and on the central regulation of appetite (9; 10), food intake (9; 11), and body weight (12). Incretin mimetics are injectable GLP-1 receptor agonists that result in pharmacological concentrations of the agonist (1) (compared to physiological concentrations of endogenous GLP-1 (4; 13; 14)). In contrast, DPP-4 inhibitors prevent the proteolytic degradation and inactivation of both GLP-1 and GIP (1; 15). These hormones are primarily thought to contribute to the insulin secretory response after meals or oral glucose challenges, while playing only a minor role at low, basal, non-nutrient-stimulated plasma concentrations (16-18). Therefore, it could be postulated that enhancement of endogenous intact incretin levels with DPP-4 inhibitors may ameliorate the defective incretin effect seen in type 2 diabetes. Despite the plausibility of this hypothesis, our previous study using vildagliptin treatment did not show any change in the numerical contribution of the incretin effect to insulin secretory responses after oral glucose challenges (19). A similar study, employing mixed meal stimulation of insulin secretion, also came to a similar conclusion (20).
DPP-4 inhibitors are most often used in conjunction with metformin (21; 22). Metformin, according to some clinical observations, may elevate concentrations of GLP-1 either through they were willing to use the same method of contraception during the full course of the study; (g) written informed consent to participate in the study.
At a screening visit, body height and weight were measured in order to calculate the body mass index (Table 1) , and blood was drawn in the fasting state for measurements of standard hematological and clinical chemistry parameters. Spot urine was sampled for the determination of albumin, protein and creatinine by standard methods. Eligible patients entered a 6-week wash-out period, if previously treated with oral antidiabetic agents. All patients entered a two-week single-blind run-in period before randomized treatment was started.
Study design.
After the run-in period, eligible patients entered the crossover study period, which consisted of four double-blind treatment periods lasting 6 days each (order randomized) with three 4-week (tolerance -3/+7 days) wash-out periods between treatments.
The incretin effect was quantified after oral treatment with sitagliptin (100 mg q.d.), metformin (dose escalation day 1, 500 mg, q.d.; day 2, 500 mg b.i.d.; day 3, 500 mg t.i.d.; days 4 to 6, 500 mg four times daily, i.e. 2000 mg/d), and metformin/sitagliptin combination or matching placebo tablets.
Experimental procedures.
The tests were performed in the morning after an overnight fast.
On day 5 of each treatment period, an oral glucose challenge (75 g of glucose and glucose oligomers; Roche O.G.T.) was given at 0 min. On day 6, 20 % glucose was administered intravenously to copy the glycemic excursions obtained after the oral glucose ("isoglycemic" intravenous glucose infusion), as previously described (19). After drawing basal blood specimens at -15 and 0 min, blood was taken at 15, 30, 45, 60, 90, 120, 180, and 240 min.
rule. Incremental responses describe changes above baseline, whereas "total" responses describe the response above zero.
Insulin secretion rates were calculated from C-peptide concentrations using software ISEC version 3.4a, kindly supplied by Dr. Roman Hovorka, London, UK (29). Population-derived coefficients of transition between compartments were used as described (30; 31).
The incretin effect was calculated based on the integrated incremental responses (trapezoidal rule) of plasma insulin, C-peptide, or insulin secretion rates following oral and "isoglycemic" intravenous glucose administration. The difference was related to the respective response after oral glucose, which was taken as 100 %. Therefore, incretin effects were expressed as the percent contribution to the total β-cell secretory response after oral glucose as previously described (2; 19).
Statistical analysis.
Patients characteristics are reported as means ± standard deviation (SD), results are reported as means ± SEM. The significance of any differences was assessed using repeated-measures analysis of covariance (ANCOVA) or analysis of variance (ANOVA), as appropriate, using Statistica Version 5.0 (Statsoft Europe, Hamburg, Germany). When comparing experiments with the oral versus intravenous administration of glucose, the type of experiment was used as the independent variable. When the four experimental treatments were to be compared (baseline values or integrated responses), the treatments (sitagliptin, metformin, either yes or no) were used as independent variables. Mean values of the parameter of interest as determined with placebo treatment were imputed as covariate.
Integrated incremental responses after oral glucose increased by 1.7-fold (both without and with a metformin background; Table 4 ).
There was no significant effect of metformin treatment on fasting total or intact GIP (Fig. 2 B, D; Fig. 3 L, P) GIP. However, sitagliptin raised fasting intact GIP (p < 0.0001; Fig. 2 D) as well as responses both before and after oral glucose (Fig. 3 O) . As expected, GIP concentrations were raised considerably more after oral glucose stimulation than during "isoglycemic" intravenous glucose infusions, when incretin levels remained in the basal range. Thus, both intact GLP-1 and intact GIP were raised slightly, but significantly after sitagliptin treatment. In the case of intact GLP-1, the concentrations remained in the "basal", i.e. low picomolar range (Fig. 2) .
Like total GLP-1 ( Fig. 3 A-D) , total GIP responses after oral glucose were significantly reduced with sitagliptin treatment by 28 % (Fig. 3 I-M; p < 0.0001; Table 4 ), but were not significantly changed by metformin treatment.
Glucose concentrations.
It was possible to closely match the glucose excursions after oral and intravenous glucose administrations ( Fig. 1 E-H) . Thus, the conditions of "isoglycemia" necessary to accurately quantify the incretin effect were met. Irrespective of treatment, oral glucose elicited a significantly higher insulin secretory response (whether based on insulin, Cpeptide, or the calculation of insulin secretion rates (Table 3 , Fig. 1, I -U).
Insulin secretion. After oral glucose, there was no significant stimulation of insulin secretory responses (insulin, C-peptide, or insulin secretion rates) by either sitagliptin or metformin treatment ( Fig. 1 K, L , O, P, S, T), except for a slight increase of C-peptide with sitagliptin treatment (Fig. 1 O, p = 0.022, asterisks). However, integrated incremental responses were higher with sitagliptin treatment (Table 4 : insulin, p = 0.0014; C-peptide, p = 0.0032, insulin secretion rates, p = 0.0076), and not significantly changed with metformin treatment (Table   4 ). The stimulatory effect of sitagliptin was observed both when used in monotherapy or in combination with metfomin ( Fig. 1 ; Table 4 ). As a result of the glucose-lowering effects of sitagliptin and metformin treatments, these enhanced insulin secretor responses occured at lower glucose concentrations. This applied to responses after both oral glucose and "isoglycemic" intravenous glucose infusions, because these were matched to those after oral glucose. Judging insulin secretory responses (insulin, C-peptide, insulin secretion rates) relative to the increment in glucose concentrations revealed a stimulation after sitagliptin treatment that did not only occur after oral glucose stimulation (when intact GLP-1 and GIP concentrations were in the "nutrient-stimulated" range of concentrations; Fig. 3 ), but also during "isoglycemic" intravenous glucose infusions (i.e., at just slightly elevated basal concentrations of intact GLP-1 and GIP; Figs. 2 and 3 ). While responses were significantly lower with "isoglycemic" intravenous glucose infusions than after oral glucose stimulation, the pattern of stimulation by sitagliptin was similar, resulting in comparable relative increments in insulin secretory responses relative to glycemic rises for both ways of administering glucose (Table 3) . If the same analysis was based in integrated incremental responses of insulin, C-peptide, or insulin secretion rates, and of glucose reponses, the conclusions were unchanged (supplementary Table) .
Incretin effect. Insulin secretion in response to oral glucose was higher than with "isoglycemic" intravenous glucose with all treatments (p < 0.0001; Table 2 ). Thus numerically, the incretin effect (placebo: 31 ± 5 %; insulin secretion, calculated from Cpeptide responses) was not significantly changed by sitagliptin (p = 0.84) or metformin treatment (p = 0.75, interaction p = 0.14; Table 2 ). The reason is that sitagliptin did not only augment insulin secretory responses (relative to glucose increments) after oral glucose stimulation, but with "isoglycemic" intravenous glucose infusions as well (Table 3) .
Glucagon. Metformin raised fasting glucagon concentrations significantly (supplementary Fig. 1 ). Glucagon concentrations were suppressed both with oral and intravenous glucose, and in a similar manner with placebo, sitagliptin, metformin, and the combinaton of sitagliptin and Fig. 2 ).
DISCUSSION
The present analysis confirms that metformin leads to an augmented secretion of GLP-1, as previously shown after two days of treatment in non-diabetic (27) and in type 2-diabetic subjects (23 administration not only stimulated insulin secretion after oral glucose (at high, nutrientstimulated incretin hormone concentrations), but also at much lower incretin levels in the basal range, i.e. as typical for the absence of nutrient stimulation (Fig. 3) , and it did do both when studied in monotherapy and as add-on to metformin. This important combination had not been examined in the previous studies on this topic. This is best illustrated by analysing the ratio of insulin secretory responses and glycemic increments, which -by definition -are very similar comparing oral glucose and "isoglycemic" intravenous glucose stimulation. The similarity of results obtained by looking at insulin, C-peptide and insulin secretion rates (deconvolution) attests to the robustness of these analyses. The surprising observation is that the small, but significant rises in fasting levels of intact, biologically active GLP-1 and GIP ( Fig. 3 , Table 4 ) introduced by DPP-4 inhibition with sitagliptin are associated with significant augmentations in insulin secretion, not only following oral glucose stimulation, but also with "isoglycemic" intravenous glucose infusions, resulting in no net change in the size of the incretin effect (Table 3) . Thus, small variations in the low concentrations of basal incretin hormone levels may determine insulin secretory responses to a greater degree than previously thought. These findings challenge the view that incretins are important in the postload, nutrient-stimulated situation but have little, if any, influence as long as their plasma concentrations are low, as in the fasting state (16; 17). However, we can only describe associations, and this cannot be used as a proof of causality.
Our finding is well compatible with the observation by Salehi et al. that a receptor antagonist at the GLP-1 receptor is able to reduce hyperglycemia-induced insulin secretory responses in the absence of nutrient stimulation (32), i.e. at low ("basal") concentrations of incretin hormones, in particular GLP-1, again indicating a relatively strong insulintropic effect at these low concentrations.
An alternative explanation could be the involvement of other mediators in addition to GLP-1. Whether GIP contributes much in patients with type 2 diabetes may be viewed highly unlikely, given the inability of exogenous GIP to stimulate insulin secretion in these subjects A surprising finding was a small, but significant rise in fasting glucagon concentrations with metformin treatment (supplementary Fig. 1 ). The difference was small, and this may be a chance finding. Alternatively, the rise in fasting glucagon may be a response to the glucoselowering effect of metformin (Fig. 1 , Table 1 Nevertheless, despite total incretin levels being reduced, sitagliptin and, to a greater extent, the combination with metformin led to an increase in intact GLP-1 levels, which likely contributes to the greater clinical effectiveness of the DPP-4 inhibitor plus metformin combination (41). Thus, insulin secretory responses relative to the glycemic increment were highest with sitagliptin plus metformin treatment, as compared to either treatment alone (Table 3, supplementary Table) .
In conclusion, treatment of patients with type 2 diabetes with metformin increases GLP-1 secretion. Treatment with the DPP-4 inhibitor sitagliptin raises plasma concentrations of intact GLP-1 and GIP both in the basal (fasting) state and after stimulation with oral glucose.
This gives rise to augmented insulin secretory responses following oral glucose and "isoglycemic" intravenous glucose infusions, resulting in the numerical size of the incretin effect being unchanged. Overall, our results indicate a prominent insulinotropic effect of small variations in incretin hormone levels in the low, "basal" range, or alternatively, other mediators, i.e. hitherto undescribed peptides, which are subject to degradation/inactivation by DPP-4, and have the ability to stimulate insulin secretion at elevated glucose concentrations. Results are reported as mean ± SEM.*analysis of variance (ANOVA). Experiments (oral vs. "isoglycemic" intravenous glucose) were used as fixed variables, and subjects as random variable, † Repeated measures analysis of covariance (ANCOVA). Treatments (sitagliptin: yes/no, metformin: yes/no) were used as independent variables; individual AUCs with placebo treatment were imputed as covariates.. OR = oral glucose load (75 g), IV = isoglycemic intravenous glucose administration, exp. = experiment, ISR = insulin secretion rate, IE = incretin effect. Table 3 Ratio of integrated total responses (∫) of insulin, C-peptide, and insulin secretion rates to integrated total glucose responses after an oral glucose load (75 g) and during the isoglycemic iv infusion of glucose. Integration was carried out from 0-240 min. Table 4 Integrated incremental responses (∫) after oral glucose load (75 g) and during the isoglycemic iv infusion of total GLP-1, intact, biologically active GLP-1, total GIP, and intact ,biologically active GIP (for time courses, see Fig. 2 ) induced by placebo, sitagliptin, metfromin or sitagliptin plus metformin administration, respectively, in patients with type 2 diabetes. investigator, were highly unlikely to sustain a recurrence during the duration of the study.
Conditions

However, patients with a history of bladder carcinoma, leukemia, lymphoma, myeloproliferative of myelodysplastic disorders, malignant melanoma, renal cell carcinoma were ineligible for the study regardless of the time since treatment, and in such cases, no exceptions were applied), (m) they were pregnant or lactating female or expecting to become pregnant within the projected duration of the study, (n) females who were expecting to donate eggs within the projected duration of the study, (o) they had HIV (as assessed by medical history), (p) they had a medical history of active liver disease including chronic active hepatitis B or C or symptomatic gallbladder disease including biliary cirrhosis, (q) they were being treated for hyperthyroidism, (r) they had any other condition or therapy which, in the opinion of the investigator might pose a risk to the patient or make participation not in the patient's best interest, (s) they were unlikely to adhere to the study procedures, keep appointments, or were planning to relocate during the study or were, as judged by the investigator to be non-eligible for the study, (t) they were, at the time of signing informed consent, a user of recreational or illicit drugs or had a recent history (within the last year) of drug or alcohol abuse or dependence (alcohol abuse includes heavy alcohol intake as defined by > 2 drinks per day or > 14 drinks per week, or binge drinking), (u) they had donated blood products or had plebotomy of > 300 mL within 2 months of signing informed consent, or intended to donate blood products or receive blood products within the projected duration of the study, (v) they had a positive urine pregnancy test, (w) they had clinically significant abnormalities of electrocardiogram, including but not limited to prolonged QTc interval (i.e., > 480 ms), 24) they had gastrointestinal (GI)surgery, chronic inflammatory bowel diseases, GI motility disorders, celiac disease, or any other GI diseases that may alter the pattern of gut hormone release after enteral stimuli (such as GIP and GLP-1 after oral glucose) at visit 1, (
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